Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses the feasibility of eliminating surgery in select patients with a pCR after neoadjuvant therapy for breast cancer.
Henry M. Kuerer, MD, PhD, FACS, CMQ
Advertisement
Henry M. Kuerer, MD, is a Professor and Executive Director Breast Programs, MD Anderson Cancer Network, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Articles by Henry M. Kuerer, MD, PhD, FACS, CMQ
Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses eliminating surgery for select patients with a pCR after neoadjuvant therapy for early breast cancer.
Dr Kuerer discusses the potential to omit surgery in patients with HER2-positive or triple-negative breast cancer who have pCR after neoadjuvant therapy.
Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses a study on selective elimination of breast surgery after exceptional response to neoadjuvant therapy in early breast cancer.
What may have worked before to mitigate burnout may no longer work now because we change, and so do our work environments.
Advertisement
Latest Updated Articles
Dr Kuerer on Selective Surgery Omission After Response to Neoadjuvant Therapy in Invasive Breast CancerPublished: April 30th 2025 | Updated:
Biopsy-Guided Approach Enables Surgery Omission After pCR in HER2+ and Triple-Negative Breast Cancer: With Henry M. Kuerer, MD, PhD, FACS, CMQPublished: July 15th 2025 | Updated:
Dr Kuerer on the Rationale for Eliminating Surgery in Select Patients With HER2+ or Triple-Negative Breast CancerPublished: July 23rd 2025 | Updated:
Burnout in Doctors and Mitigation StrategiesPublished: March 10th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5